Diseases, Conditions, Syndromes

Southeast Asian ovalocytosis protects against P. vivax malaria

A multinational group of authors, led by Ivo Mueller from the Walter & Eliza Hall Institute, Australia and the Papua New Guinea Institute of Medical Research, have found a strong association between Southeast Asian ovalocytosis, ...

Medical research

'Benign' malaria key driver of human evolution in Asia-Pacific

The malaria species rampant in the Asia-Pacific region has been a significant driver of evolution of the human genome, a new study has shown. An international team of researchers has shown that Plasmodium vivax malaria, the ...

Diseases, Conditions, Syndromes

Improving human immunity to malaria

The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells.

Diseases, Conditions, Syndromes

Study finds early signs of malaria drug resistance in Africa

Africa's deadliest malaria parasite has shown resistance in lab tests to one of the most powerful drugs on the market -- a warning of possible resistance to follow in patients, scientists said Friday.

Diseases, Conditions, Syndromes

Combination drug treatment can cut malaria by 30 percent

Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.

Medical research

Researcher invents 'lab on a chip' device to study malaria

University of British Columbia researcher Hongshen Ma has developed a simple and accurate device to study malaria, a disease that currently affects 500 million people per year worldwide and claims a million lives.

Medical research

Slamming the brakes on the malaria life cycle

Scientists have discovered a new target in their fight against the devastating global disease 'malaria' thanks to the discovery of a new protein involved in the parasite's life cycle.

Diseases, Conditions, Syndromes

Pyramax receives positive opinion from the EMA

Pyramax, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day ...

page 14 from 17